» Articles » PMID: 36687450

Methods on LDL Particle Isolation, Characterization, and Component Fractionation for the Development of Novel Specific Oxidized LDL Status Markers for Atherosclerotic Disease Risk Assessment

Abstract

The present study uses simple, innovative methods to isolate, characterize and fractionate LDL in its main components for the study of specific oxidations on them that characterize oxidized low-density lipoprotein (oxLDL) status, as it causatively relates to atherosclerosis-associated cardiovascular disease (CVD) risk assessment. These methods are: (a) A simple, relatively time-short, low cost protocol for LDL isolation, to avoid shortcomings of the currently employed ultracentrifugation and affinity chromatography methodologies. (b) LDL purity verification by apoB100 SDS-PAGE analysis and by LDL particle size determination; the latter and its serum concentration are determined in the present study by a simple method more clinically feasible as marker of CVD risk assessment than nuclear magnetic resonance. (c) A protocol for LDL fractionation, for the first time, into its main protein/lipid components (apoB100, phospholipids, triglycerides, free cholesterol, and cholesteryl esters), as well as into LDL carotenoid/tocopherol content. (d) Protocols for the measurement, for the first time, of indicative specific LDL component oxidative modifications (cholesteryl ester-OOH, triglyceride-OOH, free cholesterol-OOH, phospholipid-OOH, apoB100-MDA, and apoB100-DiTyr) out of the many (known/unknown/under development) that collectively define oxLDL status, which contrasts with the current non-specific oxLDL status evaluation methods. The indicative oxLDL status markers, selected in the present study on the basis of expressing early oxidative stress-induced oxidative effects on LDL, are studied for the first time on patients with end stage kidney disease on maintenance hemodialysis, selected as an indicative model for atherosclerosis associated diseases. Isolating LDL and fractionating its protein and main lipid components, as well as its antioxidant arsenal comprised of carotenoids and tocopherols, paves the way for future studies to investigate all possible oxidative modifications responsible for turning LDL to oxLDL in association to their possible escaping from LDL's internal antioxidant defense. This can lead to studies to identify those oxidative modifications of oxLDL (after their artificial generation on LDL), which are recognized by macrophages and convert them to foam cells, known to be responsible for the formation of atherosclerotic plaques that lead to the various CVDs.

Citing Articles

The Effect of Berry Consumption on Oxidative Stress Biomarkers: A Systematic Review of Randomized Controlled Trials in Humans.

Stote K, Burns G, Mears K, Sweeney M, Blanton C Antioxidants (Basel). 2023; 12(7).

PMID: 37507981 PMC: 10376627. DOI: 10.3390/antiox12071443.


Novel oxidized LDL-based clinical markers in peritoneal dialysis patients for atherosclerosis risk assessment.

Papadea P, Kalaitzopoulou E, Skipitari M, Varemmenou A, Papasotiriou M, Papachristou E Redox Biol. 2023; 64:102762.

PMID: 37302344 PMC: 10363433. DOI: 10.1016/j.redox.2023.102762.

References
1.
Shoji T, Kimoto E, Shinohara K, Emoto M, Ishimura E, Miki T . The association of antibodies against oxidized low-density lipoprotein with atherosclerosis in hemodialysis patients. Kidney Int Suppl. 2003; (84):S128-30. DOI: 10.1046/j.1523-1755.63.s84.37.x. View

2.
Fellstrom B, Jardine A, Schmieder R, Holdaas H, Bannister K, Beutler J . Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. N Engl J Med. 2009; 360(14):1395-407. DOI: 10.1056/NEJMoa0810177. View

3.
Di Pietro N, Formoso G, Pandolfi A . Physiology and pathophysiology of oxLDL uptake by vascular wall cells in atherosclerosis. Vascul Pharmacol. 2016; 84:1-7. DOI: 10.1016/j.vph.2016.05.013. View

4.
Carmena R, Ascaso J, Redon J . Chronic kidney disease as a cardiovascular risk factor. J Hypertens. 2020; 38(11):2110-2121. DOI: 10.1097/HJH.0000000000002506. View

5.
Romanchik J, Morel D, Harrison E . Distributions of carotenoids and alpha-tocopherol among lipoproteins do not change when human plasma is incubated in vitro. J Nutr. 1995; 125(10):2610-7. DOI: 10.1093/jn/125.10.2610. View